ADXS - Advaxis, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Monmouth Junction,
United States
Type: Equity
ADXS price evolution
ADXS
| (in millions $) | 31 Mar 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16.84 | $25.21 | $28.15 | $32.09 |
| Short term investments | $0.11 | |||
| Net receivables | $0 | |||
| Inventory | ||||
| Total current assets | $18.26 | $25.76 | $29.82 | $34.18 |
| Long term investments | ||||
| Property, plant & equipment | $2.39 | $0.05 | $0.09 | $0.11 |
| Goodwill & intangible assets | $0.13 | $0.11 | $0.18 | $3.22 |
| Total noncurrent assets | $2.73 | $0.17 | $0.28 | $3.34 |
| Total investments | $0.11 | |||
| Total assets | $21 | $25.93 | $30.1 | $37.52 |
| Current liabilities | ||||
| Accounts payable | $5.83 | $0.02 | $0.09 | $0.04 |
| Deferred revenue | ||||
| Short long term debt | $0.25 | $0.01 | $0.02 | $0.03 |
| Total current liabilities | $9.83 | $2.3 | $1.91 | $2.37 |
| Long term debt | $1.41 | |||
| Total noncurrent liabilities | $1.49 | |||
| Total debt | $1.66 | $0.01 | $0.02 | $0.03 |
| Total liabilities | $11.32 | $2.3 | $1.91 | $2.37 |
| Shareholders' equity | ||||
| Retained earnings | -$156.51 | -$442.96 | -$438.37 | -$431.4 |
| Other shareholder equity | ||||
| Total shareholder equity | $9.68 | $23.63 | $28.2 | $35.15 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.21 | $41.61 | $25.18 | $32.36 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $25.76 | $43.26 | $27.85 | $36.15 |
| Long term investments | ||||
| Property, plant & equipment | $0.05 | $0.16 | $7.23 | $4.35 |
| Goodwill & intangible assets | $0.11 | $3.35 | $3.26 | $4.58 |
| Total noncurrent assets | $0.17 | $3.52 | $10.68 | $9.11 |
| Total investments | ||||
| Total assets | $25.93 | $46.78 | $38.53 | $45.26 |
| Current liabilities | ||||
| Accounts payable | $0.02 | $0.09 | $0.41 | $0.98 |
| Deferred revenue | $0.17 | |||
| Short long term debt | $0.01 | $0.03 | $0.96 | |
| Total current liabilities | $2.3 | $7.88 | $3.29 | $4.52 |
| Long term debt | $0.01 | $5.05 | ||
| Total noncurrent liabilities | $0.01 | $5.05 | $1.21 | |
| Total debt | $0.01 | $0.04 | $6.02 | |
| Total liabilities | $2.3 | $7.89 | $8.35 | $5.73 |
| Shareholders' equity | ||||
| Retained earnings | -$442.96 | -$428.6 | -$410.74 | -$384.27 |
| Other shareholder equity | ||||
| Total shareholder equity | $23.63 | $38.89 | $30.18 | $39.53 |
| (in millions $) | 31 Mar 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0 | $0.25 | ||
| Cost of revenue | $0 | |||
| Gross Profit | $0.25 | |||
| Operating activities | ||||
| Research & development | $7.26 | $2.25 | $2.23 | $1.48 |
| Selling, general & administrative | $4.6 | $2.56 | $2.05 | $1.77 |
| Total operating expenses | $11.87 | $4.85 | $7.29 | $3.25 |
| Operating income | -$11.87 | -$4.85 | -$7.29 | -$3 |
| Income from continuing operations | ||||
| EBIT | -$11.57 | -$4.59 | -$6.96 | -$2.39 |
| Income tax expense | -$4.21 | $0.05 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$7.36 | -$4.59 | -$6.96 | -$2.44 |
| Income (for common shares) | -$7.36 | -$4.59 | -$6.96 | -$3.46 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.25 | $3.24 | $0.25 | $20.88 |
| Cost of revenue | ||||
| Gross Profit | $0.25 | $3.24 | $0.25 | $20.88 |
| Operating activities | ||||
| Research & development | $7.62 | $10.56 | $15.61 | $26.68 |
| Selling, general & administrative | $8.89 | $11.46 | $11.09 | $12.18 |
| Total operating expenses | $19.56 | $22.03 | $26.7 | $38.86 |
| Operating income | -$19.31 | -$18.79 | -$26.45 | -$17.97 |
| Income from continuing operations | ||||
| EBIT | -$14.31 | -$17.81 | -$26.42 | -$16.56 |
| Income tax expense | $0.05 | $0.05 | $0.05 | $0.05 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$14.36 | -$17.86 | -$26.47 | -$16.61 |
| Income (for common shares) | -$15.38 | -$17.86 | -$26.47 | -$16.61 |
| (in millions $) | 31 Mar 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Net income | -$7.36 | -$4.59 | -$6.96 | -$2.44 |
| Operating activities | ||||
| Depreciation | $0.04 | $0.01 | $0.02 | $0.02 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.19 | $0.02 | $0.03 | $0.02 |
| Total cash flows from operations | -$6.74 | -$2.98 | -$3.85 | -$4.32 |
| Investing activities | ||||
| Capital expenditures | $0.04 | |||
| Investments | ||||
| Total cash flows from investing | $0.04 | -$0.07 | -$0.08 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.02 | |||
| Net borrowings | ||||
| Total cash flows from financing | $21.2 | -$0.02 | -$5.25 | |
| Effect of exchange rate | -$0.04 | |||
| Change in cash and equivalents | $14.42 | -$2.94 | -$3.94 | -$9.64 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$14.36 | -$17.86 | -$26.47 | -$16.61 |
| Operating activities | ||||
| Depreciation | $0.08 | $0.72 | $1.64 | $1.1 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.1 | $0.57 | $0.89 | $2 |
| Total cash flows from operations | -$15.28 | -$15.44 | -$21.94 | -$36.13 |
| Investing activities | ||||
| Capital expenditures | $0.04 | $0.45 | $0.03 | |
| Investments | ||||
| Total cash flows from investing | -$0.17 | -$0.01 | -$0.75 | -$1.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.02 | $31.89 | $15.5 | $24.49 |
| Net borrowings | ||||
| Total cash flows from financing | -$0.96 | $31.89 | $15.5 | $24.57 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$16.41 | $16.44 | -$7.18 | -$12.76 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $254.00K |
|---|---|
| EBITDA | -$25.41M |
| EBIT | -$25.51M |
| Net Income | -$21.36M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -74.57% |
| ROE | -88.38% |
| Debt/Equity | 0.10 |
|---|---|
| Net debt/EBITDA | 0.22 |
| Current ratio | 1.86 |
| Quick ratio | 1.86 |